The reporter of China Securities News learned that at 18:00 on April 3, 14 40 foot containers of lianhuaqing plague prevention materials worth 50 million yuan sent by Shijiazhuang freight center to Shanghai were loaded. The special train quickly departed from the West freight yard of Shijiazhuang freight center to Shanghai Yangpu station. This is Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) combined with the needs of the epidemic situation in Shanghai, through the "Lianhua respiratory health public welfare line" project of the Chinese Red Cross foundation, and after donating 10 million yuan Lianhua to Shanghai on March 28 to clear the plague, another emergency donation of 50 million yuan Lianhua to clear the plague, so as to help the local epidemic prevention and control.
Recently, the epidemic situation in China is grim. The transmission speed of Omicron virus strain is fast, the incubation period is short, and the proportion of recessive infections or mild cases is high, which increases the difficulty of prevention and control. In the local epidemic situation in Shanghai, it shows the characteristics of multi-point distribution, multi chain parallel and hidden transmission, in which the proportion of light and asymptomatic infections is high.
At the press conference on epidemic prevention and control in Shanghai held on March 30, Wu Yingen, a lifelong professor at Longhua Hospital Affiliated to Shanghai University of traditional Chinese medicine, pointed out that Lianhua Qingwen can be used for the treatment of mild or asymptomatic covid-19 patients. The latest research shows that Lianhua Qingwen has a good inhibitory effect on Omicron virus, and it also has an inhibitory effect on the cell damage of Omicron virus in human body.
Lianhua Qingwen is a patent medicine for preventing influenza, influenza and COVID-19 pneumonia. It is a representative drug for China to deal with respiratory tract virus infectious public health events, and is an effective drug selected for treating COVID-19 pneumonia with Chinese medicine. It is included in the New Coronavirus pneumonia diagnosis and treatment plan jointly issued by the national Health Protection Commission and the State Administration of traditional Chinese medicine.
Zhang Yunling, executive deputy general manager of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) introduced: "in January 2021, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) donated 50 million yuan of money and materials to the Red Cross Foundation of China and initiated the establishment of the 'Lianhua respiratory health public welfare bank' project. So far, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) has donated 130 million yuan of materials to 17 provinces (autonomous regions and municipalities directly under the central government) Donate epidemic prevention materials to benefit front-line medical workers, volunteers, community workers, sanitation workers, takeout couriers, police, teachers, students, empty nesters and other groups. In addition, in 2021, the project helped prevent and control the post earthquake epidemic situation in Yunnan and Qinghai, rushed to flood control and disaster relief in Henan and Shanxi, and continued to contribute to the cause of the Red Cross. "
